Home › Funds › Rock Springs Capital Management LP › NBIX
Rock Springs Capital Management LP position in NBIX
NEUROCRINE BIOSCIENCES INC · Health Care
Rock Springs Capital Management LP reported holding 130,500 shares of NBIX (NEUROCRINE BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$18.5M, representing 1.00% of its reported portfolio and ranking #33 among its reported holdings. Rock Springs Capital Management LP has disclosed NBIX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Rock Springs Capital Management LP's NBIX position evolved
Rock Springs Capital Management LP first disclosed a stake in NBIX in Q3 2023 at 1,000,000 shares (US$1.5M). The position peaked in Q2 2024 at 940,000 shares, worth US$129.4M. Across 13 filings, Rock Springs Capital Management LP increased the stake 3 time(s), trimmed it 6 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 130,500 shares valued at US$18.5M — a reduction of -14,250 shares quarter over quarter.. Notable position changes include a 61% trim in Q1 2025 (shares rose 14% over the following quarter), a 68% trim in Q2 2025 (shares rose 12% over the following quarter), a 40% increase in Q4 2025 (shares fell 7% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.00M | $1.50M | New |
| Q4 2023 | 1.00M | $1.75M | Hold |
| Q1 2024 | 1.00M | $1.81M | Hold |
| Q2 2024 | 940.00K | $129.41M | Reduce |
| Q3 2024 | 939.00K | $108.19M | Hold |
| Q4 2024 | 720.50K | $98.35M | Reduce |
| Q1 2025 | 279.00K | $30.86M | Reduce |
| Q2 2025 | 88.80K | $11.16M | Reduce |
| Q3 2025 | 89.75K | $12.60M | Add |
| Q4 2025 | 125.50K | $17.80M | Add |
| Q1 2026 | 150.45K | $19.82M | Add |
| Q2 2026 | 144.75K | $24.40M | Reduce |
| Q3 2026 | 130.50K | $18.51M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NBIX and 13F data
NBIX (NEUROCRINE BIOSCIENCES INC) is a Health Care company. 29 other funds we track also report a position in NBIX — the largest reported positions include Renaissance Technologies (US$326.3M), Vestal Point Capital, LP (US$316.8M), RTW INVESTMENTS, LP (US$133.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NBIX
- Renaissance Technologies 2.30M sh · $326.33M · Q3 2026
- Vestal Point Capital, LP 1.88M sh · $316.85M · Q2 2026
- RTW INVESTMENTS, LP 942.68K sh · $133.71M · Q3 2026
More on Rock Springs Capital Management LP
FAQ
How long has Rock Springs Capital Management LP held NBIX?
Rock Springs Capital Management LP has disclosed NBIX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Rock Springs Capital Management LP's current position in NBIX?
As of Q3 2026, Rock Springs Capital Management LP holds 130.50K shares of NBIX (NEUROCRINE BIOSCIENCES INC), valued at $18.51M, representing 1.00% of its reported portfolio and ranking #33.
Has Rock Springs Capital Management LP been buying or selling NBIX?
In the latest 13F filing (Q3 2026), Rock Springs Capital Management LP reduced its position in NBIX. The position peaked in Q2 2024 at 940.00K shares.
Which other funds hold NBIX?
Other major institutional holders of NBIX include Renaissance Technologies, Vestal Point Capital, LP, RTW INVESTMENTS, LP, among 29 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.